FDA 执法报告 D-0049-2027 将 Viatris 替米沙坦氨氯地平片超效价召回列为 III 类
FDA drug enforcement D-0049-2027: Viatris, Inc. — Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications
openFDA 执法报告 D-0049-2027 记录 Viatris 公司自愿召回替米沙坦氨氯地平片 40mg/5mg(30 片/瓶),原因是相关批次替米沙坦含量可能超出标准,属于超效价风险,被列为 III 类。
记录给出了超效价风险涉及的具体批号、有效期与分销范围,可用于核对召回边界与批次覆盖。
FDA drug recall enforcement report — D-0049-2027
Report issued: 2026-10-28. This is the enforcement report date, not the recall initiation date.
Scope: one classified drug product recall record; event_id may group multiple products. Unclassified records without recall numbers are outside this stream. This record is not a press release or a new enforcement finding.
The openFDA dataset is updated weekly. Report status is not a live recall status and must not be used to track the recall lifecycle. Other dates below retain their named meanings.
Complete official product record (including openFDA harmonized identifiers):
{
"address_1": "3711 Collins Ferry Rd",
"address_2": "",
"center_classification_date": "20261016",
"city": "Morgantown",
"classification": "Class III",
"code_info": "Lot # 3228113, 3228114, 3228115, Exp Date: Oct 31, 2026; Lot # 3228120, 3228121, Exp Date: Nov 30, 2026.",
"country": "United States",
"distribution_pattern": "Nationwide in the USA.",
"event_id": "100048",
"initial_firm_notification": "Letter",
"more_code_info": "",
"openfda": {
"application_number": [
"ANDA202516"
],
"brand_name": [
"TELMISARTAN AND AMLODIPINE"
],
"generic_name": [
"TELMISARTAN AND AMLODIPINE"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Mylan Pharmaceuticals Inc."
],
"nui": [
"N0000000070",
"N0000175561"
],
"package_ndc": [
"0378-1075-93",
"0378-1076-93",
"0378-1077-93",
"0378-1078-93"
],
"pharm_class_epc": [
"Angiotensin 2 Receptor Blocker [EPC]"
],
"pharm_class_moa": [
"Angiotensin 2 Receptor Antagonists [MoA]"
],
"product_ndc": [
"0378-1075",
"0378-1076",
"0378-1077",
"0378-1078"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"ORAL"
],
"rxcui": [
"876514",
"876519",
"876524",
"876529"
],
"spl_id": [
"c4f4323d-671d-478b-b088-008530932cee"
],
"spl_set_id": [
"ca60a4d5-ace7-4889-94ee-e2265fd63811"
],
"substance_name": [
"TELMISARTAN",
"AMLODIPINE BESYLATE"
],
"unii": [
"U5SYW473RQ",
"864V2Q084H"
],
"upc": [
"0303781075930",
"0303781076937",
"0303781078931",
"0303781077934"
]
},
"postal_code": "26505-2362",
"product_description": "Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in India, NDC 0378-1075-93.",
"product_quantity": "21,620 30-count bottles",
"product_type": "Drugs",
"reason_for_recall": "Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications",
"recall_initiation_date": "20261001",
"recall_number": "D-0049-2027",
"recalling_firm": "Viatris, Inc.",
"report_date": "20261028",
"state": "WV",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov